IL228633B - Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) - Google Patents

Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Info

Publication number
IL228633B
IL228633B IL228633A IL22863313A IL228633B IL 228633 B IL228633 B IL 228633B IL 228633 A IL228633 A IL 228633A IL 22863313 A IL22863313 A IL 22863313A IL 228633 B IL228633 B IL 228633B
Authority
IL
Israel
Prior art keywords
tfpi
monoclonal antibodies
antibodies against
tissue factor
pathway inhibitor
Prior art date
Application number
IL228633A
Other languages
English (en)
Hebrew (he)
Other versions
IL228633A0 (en
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL228633(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IL228633A0 publication Critical patent/IL228633A0/en
Publication of IL228633B publication Critical patent/IL228633B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL228633A 2011-04-01 2013-09-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) IL228633B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
PCT/US2012/031538 WO2012135671A2 (en) 2011-04-01 2012-03-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (2)

Publication Number Publication Date
IL228633A0 IL228633A0 (en) 2013-12-31
IL228633B true IL228633B (en) 2018-03-29

Family

ID=46932389

Family Applications (4)

Application Number Title Priority Date Filing Date
IL228633A IL228633B (en) 2011-04-01 2013-09-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL257145A IL257145A (en) 2011-04-01 2018-01-25 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL274686A IL274686B (en) 2011-04-01 2020-05-14 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL283829A IL283829A (en) 2011-04-01 2021-06-09 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL257145A IL257145A (en) 2011-04-01 2018-01-25 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL274686A IL274686B (en) 2011-04-01 2020-05-14 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL283829A IL283829A (en) 2011-04-01 2021-06-09 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (enExample)
EP (1) EP2694544B1 (enExample)
JP (4) JP6170903B2 (enExample)
KR (2) KR101995302B1 (enExample)
CN (2) CN107090046A (enExample)
AU (3) AU2012236296A1 (enExample)
BR (1) BR112013025376A2 (enExample)
CA (2) CA3068997A1 (enExample)
CL (1) CL2013002811A1 (enExample)
CO (1) CO6890074A2 (enExample)
CR (1) CR20130499A (enExample)
CU (1) CU20130128A7 (enExample)
CY (1) CY1121538T1 (enExample)
DK (1) DK2694544T3 (enExample)
DO (1) DOP2013000218A (enExample)
EA (2) EA034214B1 (enExample)
EC (1) ECSP13012913A (enExample)
ES (1) ES2722824T3 (enExample)
GT (1) GT201300229A (enExample)
HK (1) HK1243426A1 (enExample)
HR (1) HRP20190467T1 (enExample)
HU (1) HUE042706T2 (enExample)
IL (4) IL228633B (enExample)
LT (1) LT2694544T (enExample)
MX (1) MX2013011218A (enExample)
MY (2) MY165499A (enExample)
PE (1) PE20141149A1 (enExample)
PH (4) PH12013502039A1 (enExample)
PL (1) PL2694544T3 (enExample)
PT (1) PT2694544T (enExample)
RS (1) RS58633B1 (enExample)
SG (2) SG10201602606UA (enExample)
SI (1) SI2694544T1 (enExample)
TR (1) TR201905101T4 (enExample)
UA (1) UA113623C2 (enExample)
WO (1) WO2012135671A2 (enExample)
ZA (1) ZA201308169B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984319B (zh) 2008-12-19 2025-05-09 武田药品工业株式会社 Tfpi抑制剂和使用方法
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
EP3260466A1 (en) 2008-12-22 2017-12-27 Novo Nordisk A/S Anti-tfpi antibodies
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN107090046A (zh) * 2011-04-01 2017-08-25 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
JP2015514070A (ja) * 2012-03-21 2015-05-18 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Tfpi阻害剤および使用方法
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2970499B1 (en) 2013-03-15 2022-08-10 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
EP2970497B1 (en) 2013-03-15 2017-10-25 Bayer HealthCare LLC Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
JP6584397B2 (ja) * 2013-07-19 2019-10-02 ノヴォ ノルディスク アー/エス 凝血促進活性を誘発することができる組織因子経路インヒビターのn末端部分を認識する抗体
JP6783754B2 (ja) * 2014-09-17 2020-11-11 ノヴォ ノルディスク アー/エス 組織因子経路インヒビター(1〜161)上の2つのエピトープに結合する能力がある抗体
CA2977621C (en) * 2015-02-25 2021-11-23 Mogam Institute For Biomedical Research Antibody binding to tfpi and composition comprising the same
CN107922506B (zh) * 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP3260466A1 (en) * 2008-12-22 2017-12-27 Novo Nordisk A/S Anti-tfpi antibodies
LT3345615T (lt) * 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN107090046A (zh) * 2011-04-01 2017-08-25 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Also Published As

Publication number Publication date
US20180194857A1 (en) 2018-07-12
EP2694544A2 (en) 2014-02-12
CA2831907A1 (en) 2012-10-04
AU2017203105A1 (en) 2017-06-01
MY165499A (en) 2018-03-27
US20140294832A1 (en) 2014-10-02
PT2694544T (pt) 2019-04-02
SG193594A1 (en) 2013-10-30
DOP2013000218A (es) 2013-11-15
JP2018172411A (ja) 2018-11-08
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
EA201301107A1 (ru) 2014-11-28
CN103797030B (zh) 2017-05-31
RS58633B1 (sr) 2019-05-31
EA034214B1 (ru) 2020-01-17
BR112013025376A2 (pt) 2017-07-25
CU20130128A7 (es) 2014-03-26
IL257145A (en) 2018-03-29
IL274686A (en) 2020-06-30
JP2021019619A (ja) 2021-02-18
PH12019500439A1 (en) 2020-10-12
NZ615969A (en) 2016-01-29
CR20130499A (es) 2013-10-24
KR20190079698A (ko) 2019-07-05
JP2014511685A (ja) 2014-05-19
CL2013002811A1 (es) 2014-02-28
IL283829A (en) 2021-07-29
US20170107298A1 (en) 2017-04-20
GT201300229A (es) 2014-11-13
HRP20190467T1 (hr) 2019-05-03
PH12019500441A1 (en) 2020-10-12
AU2019201814A1 (en) 2019-04-04
ES2722824T3 (es) 2019-08-19
PH12013502039B1 (en) 2013-12-16
KR101995302B1 (ko) 2019-07-02
CO6890074A2 (es) 2014-03-10
MX2013011218A (es) 2013-10-17
CN103797030A (zh) 2014-05-14
UA113623C2 (uk) 2017-02-27
CA3068997A1 (en) 2012-10-04
US20190194353A1 (en) 2019-06-27
SI2694544T1 (sl) 2019-06-28
WO2012135671A2 (en) 2012-10-04
CY1121538T1 (el) 2020-05-29
DK2694544T3 (en) 2019-04-15
LT2694544T (lt) 2019-04-25
PE20141149A1 (es) 2014-08-28
CN107090046A (zh) 2017-08-25
HK1243426A1 (zh) 2018-07-13
CA2831907C (en) 2020-03-24
EA201991704A3 (ru) 2020-06-30
ECSP13012913A (es) 2014-02-28
EP2694544A4 (en) 2015-03-25
HUE042706T2 (hu) 2019-07-29
WO2012135671A3 (en) 2012-12-13
TR201905101T4 (tr) 2019-05-21
PH12013502039A1 (en) 2013-12-16
ZA201308169B (en) 2016-03-30
JP6363747B2 (ja) 2018-07-25
EP2694544B1 (en) 2019-01-23
SG10201602606UA (en) 2016-04-28
EA201991704A2 (ru) 2020-03-31
US20220041752A1 (en) 2022-02-10
IL274686B (en) 2021-09-30
PL2694544T3 (pl) 2019-07-31
KR20140019428A (ko) 2014-02-14
JP2017113019A (ja) 2017-06-29
IL228633A0 (en) 2013-12-31
JP6170903B2 (ja) 2017-07-26
AU2012236296A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
IL283829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL277391A (en) Monoclonal antibodies are effective against tissue factor pathway inhibitor (TFPI)
ZA201400768B (en) Interleukin-31 monoclonal antibody
IL220404A (en) Antiseptic antibodies
IL210987A (en) Monoclonal antibodies against tissue pathogen inhibitor (TFPI)
SMT201600193B (it) Nuovo anticorpo anti-dr5
ZA201206835B (en) New humanized anti-cd20 monoclonal antibory
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed